TOMI Environmental Solutions, Inc.® (NASDAQ: TOMZ) shares headed upward Monday. The company, claiming to be a global leader in disinfection and decontamination solutions, today reported strong momentum in the compounding pharmacy sector, with approximately a dozen client partnerships. This growth is driven by a heightened demand for validated decontamination technologies as pharmacies face increasingly stringent regulatory oversight and rigorous FDA audits.
The compounding pharmacy industry is currently undergoing a period of intense regulatory transformation, with facilities categorized under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act facing higher stakes than ever before. Traditional 503A pharmacies, which provide patient-specific medications, and 503B outsourcing facilities, which manufacture larger batches for hospital and clinic use, must both adhere to rigorous standards such as USP for sterile compounding and USP for the handling of hazardous drugs. For 503B facilities specifically, the requirement to maintain current Good Manufacturing Practice (cGMP) standards creates a manufacturing-level burden of proof for cleanliness and environmental control that many traditional cleaning methods simply cannot meet.
"The compounding pharmacy industry is at a crossroads where manual cleaning is no longer sufficient to meet modern FDA expectations," said COO Elissa J. (E.J.) Shane. "Our growth in this sector, particularly among 503B outsourcers, reflects a shift toward automated, validated technology. The increasing volume of ongoing solution orders proves that our customers view SteraMist not just as a one-time purchase, but as an essential, everyday partner in maintaining the highest standards of patient safety and regulatory standing.”
TOMI shares gained two cents, or 2.6%, to 62 cents.
Related Stories
